We are live on ! Find out more
AGRX

Agile Therapeutics
AGRX

Delisted

AGRX was delisted on the 25th of March, 2024.

Back to rankings

79 hedge funds and large institutions have $107M invested in Agile Therapeutics in 2020 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

209% more call options, than puts

Call options by funds: $1.53M | Put options by funds: $497K

136% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 14

110% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 10

74% more capital invested

Capital invested by funds: $61.4M → $107M (+$45.5M)

30% more funds holding

Funds holding: 61 → 79 (+18)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
79
Holders Change
+18
Holders Change %
+29.51%
% of All Funds
1.62%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
33
Increased
21
Reduced
10
Closed
14
Calls
$1.53M
Puts
$497K
Net Calls
+$1.04M
Net Calls Change
+$303K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$10.1M
2
State Street
State Street
Massachusetts
+$2.6M
3
Northern Trust
Northern Trust
Illinois
+$1.87M
4
DCM
DG Capital Management
New York
+$1.47M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.31M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$2.23M
2
Renaissance Technologies
Renaissance Technologies
New York
-$2.2M
3
Millennium Management
Millennium Management
New York
-$1.98M
4
EP
Eversept Partners
New York
-$1.32M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
76
Procyon Advisors
Connecticut
$7K – – –
APWA
77
Atlas Private Wealth Advisors
New Jersey
$7K +$5.2K +1 New
AF
78
Advisornet Financial
Minnesota
$6K +$5.2K +1 New
SIS
79
Sound Income Strategies
Florida
$3K – – –
TWA
80
TCI Wealth Advisors
Arizona
$1K – – –
O
81
OrbiMed
New York
– -$2.23M -600 Closed
EP
82
Eversept Partners
New York
– -$1.32M -356 Closed
LCM
83
Laurion Capital Management
New York
– -$233K -63 Closed
Goldman Sachs
84
Goldman Sachs
New York
– -$118K -32 Closed
CS
85
Credit Suisse
Switzerland
– -$90K -24 Closed
ECM
86
ExodusPoint Capital Management
New York
– -$71K -19 Closed
AAP
87
Ardsley Advisory Partners
Connecticut
– -$37K -10 Closed
Macquarie Group
88
Macquarie Group
Australia
– -$33K -9 Closed
Man Group
89
Man Group
United Kingdom
– -$29K -8 Closed
RJFSA
90
Raymond James Financial Services Advisors
Florida
– -$26K -7 Closed
AGM
91
Alpine Global Management
New York
– -$24K -6 Closed
JG
92
Jefferies Group
New York
– -$22K -6 Closed
ER
93
Enlightenment Research
Florida
– -$28K -5 Closed
Simplex Trading
94
Simplex Trading
Illinois
– -$20.8K -4 Closed
ASN
95
Advisory Services Network
Georgia
– -$1K – –
Federated Hermes
96
Federated Hermes
Pennsylvania
– -$1K – –
1 2 3
4

AGRX Hedge Fund Activity: Q2 2020 in Review

79 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q2 2020, worth a combined $107M — up 74% from $61.4M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new AGRX positions and 14 closed out — a net gain of 19 holders — while 21 added to existing stakes and 10 trimmed.

The largest buyer was BlackRock, adding an estimated $10.1M. The largest seller was OrbiMed, exiting entirely with an estimated $2.23M sold.

  • 79 institutional investors held Agile Therapeutics (AGRX) as of Q2 2020, up from 61 in Q1 2020.
  • Funds reported $107M of Agile Therapeutics stock for Q2 2020, up 74% quarter-over-quarter.
  • 33 funds opened new Agile Therapeutics positions in Q2 2020 and 14 closed out, a net change of +19 holders.
  • The largest Agile Therapeutics buyer in Q2 2020 was BlackRock, an estimated $10.1M added.
  • The largest Agile Therapeutics seller in Q2 2020 was OrbiMed, an estimated $2.23M sold.

Based on aggregated 13F filings for Q2 2020.